Skip to main content
All lobbying filings

Grifols Shared Services North America, Inc.

Grifols Shared Services North America, Inc. filed a Q2 report for Grifols Shared Services North America Inc. on July 16, 2025.

Lobbying for Grifols Shared Services North America Inc.

As filed: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. for GRIFOLS SHARED SERVICES NORTH AMERICA INC.

All filings by Grifols Shared Services North America, Inc. · Everything Grifols Shared Services North America Inc. has reported

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2025
Apr 1 - June 30 · Posted Jul 16, 2025
Expenses
$390,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 4
Health Issues

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion Act S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act H.R. 3493, Global Fairness in Drug Pricing Act

Immigration

Issues related to immigration policy

Budget/Appropriations

FY2026 Appropriations bill for Health and Human Services; Medicare and Medicaid drug pricing and eligibility FY2026 Appropriations bill for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies; Blood Safety and Pathogen Reduction H.R. 1, One Big, Beautiful Bill Act; Medicare provisions - Most Favored Nations and drug pricing, Medicaid provisions - PBM Reform and eligibility, R&D tax credits

Tariff (miscellaneous tariff bills)

Issues related to tariff policy; tariffs on pharmaceuticals and related products

 Bills named in this filing 12
  • H.R. 1476
    PLASMA Act
  • S. 694
    PLASMA Act
  • H.R. 1143
    Medicare IVIG Access Enhancement Act of 2025
  • H.R. 2343
    John W. Walsh Alpha-1 Home Infusion Act of 2025
  • H.R. 2172
    Preserving Patient Access to Home Infusion Act
  • S. 1818
    Prescription Drug Price Relief Act of 2025
  • H.R. 3546
    Prescription Drug Price Relief Act of 2025
  • S. 1587
    Fair Prescription Drug Prices for Americans Act
  • H.R. 3375
    Fair Prescription Drug Prices for Americans Act
  • S. 1753
    End Price Gouging for Medications Act
  • H.R. 3493
    Global Fairness in Drug Pricing Act
  • H.R. 1
    One Big Beautiful Bill Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem